BRUSSELS, Belgium, Aug. 26, 2005 (PRIMEZONE) -- UCB today announces the divestment of Celltech Manufacturing Services Ltd., in Ashton, U.K., a UCB subsidiary carrying out contract manufacturing. The subsidiary has been acquired by U.S. company Inyx Incorporated for EUR 27.5 million. Inyx is a speciality pharmaceutical company focusing on niche drug delivery technologies.
About UCB
UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra(R) (antiepileptic), Xyzal(R) and Zyrtec(R) (antiallergics), Nootropil(R) (cerebral function regulator), Tussionex(TM) (antitussive) and Metadate(TM)/ Equasym XL(TM) (attention-deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels with a market capitalization of approximately EUR 6.8 billion.
For enquiries, please contact:
Jean-Christophe Donck Vice President Corporate Communication & Investor Relations Phone +32 2 559 9588 Fax +32 2 559 9571 Email JC.Donck@UCB-Group.com
To see the pdf-version of this press release, please click on the link below: